首页> 外文期刊>Bulletin of the Korean Chemical Society >Synthesis and Biological Evaluation of Decursinol Derivatives as FoxO- 1 Inhibitors in HepG2 Cells
【24h】

Synthesis and Biological Evaluation of Decursinol Derivatives as FoxO- 1 Inhibitors in HepG2 Cells

机译:Depsinol衍生物作为HepG2细胞Foxo-1抑制剂的合成与生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

Diabetes mellitus type 2 is caused by insulin resistance, often associated with increased hepatic gluconeo-genesis. Forkhead box 0-1 (FoxO-1) is known as a major transcription factor regulating hepatic gluconeo-genesis, and the increased FoxO-1 expression and activity are mainly observed in type 2 diabetic patients. To discover new FoxO-1 inhibitors, the compounds were newly synthesized from decursinol, which is a molecule isolated from the Angelica gigas and proved to be safe. The compounds were evaluated for in vitro FoxO-1 inhibitory activity using FoxO-1 reporter assay in HepG2 cells. Among these, the compounds 2b and 2c exhibited FoxO-1 inhibitory activity with IC50 values of 98.9 and 123.7 uM, respectively. Moreover, the blood glucose level reduction efficacy of synthesized compound 2b was found similar to that of glimepiride, a commercially available antidiabetic drug and used as a reference (21.6 vs. 21.4%), in alloxan-induced type 2 diabetes rats. These findings suggest that, the compound 2b has moderate inhibitory activity on FoxO-1 and possibly resulting in the amelioration of diabetic hyperglycemia.
机译:糖尿病型2是由胰岛素抗性引起的,通常与肝葡糖葡聚糖的增加相关。 FORKHEAD盒0-1(FOXO-1)被称为调节肝葡糖基因的主要转录因子,并且在2型糖尿病患者中主要观察到的FOXO-1表达和活性增加。为了发现新的FOXO-1抑制剂,将该化合物新合成二磺尼,这是从Angelica Gigas分离的分子并证明是安全的。在HepG2细胞中使用FoxO-1报告测定评估该化合物的体外FoxO-1抑制活性。其中,化合物2b和2c分别显示出FoxO-1抑制活性,分别具有98.9和123.7μm的IC 50值。此外,已发现合成化合物2B的血糖水平降低效果类似于胶质脂素,市售的抗糖尿病药物,并用作阿内苏氏诱导的2型糖尿病大鼠的参考(21.6〜21.4%)。这些发现表明,化合物2B对FoxO-1具有中等的抑制活性,并可能导致糖尿病高血糖的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号